Glucagon-like peptide analogues for type 2 diabetes mellitus

Cochrane Database of Systematic Reviews

Volumn , Issue 1, 2007, Pages

  Snaith, Alisa ^a   McIntyre, L ^b   Rothnie, H ^b   Thomas, S ^b   Royle, P ^b   Waugh, N ^b  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; INSULIN; LIRAGLUTIDE; METFORMIN; PEPTIDE DERIVATIVE; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE;

CLINICAL TRIAL; COCHRANE LIBRARY; DATA ANALYSIS; DATA EXTRACTION; DRUG EFFECT; DRUG EFFICACY; EMBASE; HUMAN; INFORMATION RETRIEVAL; MEDICAL LITERATURE; MEDLINE; METHODOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PUBLICATION; REVIEW; TREATMENT OUTCOME;

EID: 44949089679     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006423     Document Type: Review

References (36)

1. Abraham 2002 Abraham EJ, Leech CA, Lin JC, Zulewski H, Habener JF. Insulinotropic hormone glucagon-like peptide-1 differentiation of human pancreatic islet-derived progenitor cells into insulin-producing cells. Endocrinology 2002;143(8):3152-61.
2. ADA 1997 American Diabetes Association. Report on the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20 Suppl 1:S5-20.
3. ADA 1999 The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1999;22 Suppl 1:S5-19.
4. Baggio 2004 Baggio LL, Huang Q, Brown TJ, Drucker DJ. A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes 2004;53(9):2492-500.
5. Bullock 1996 Bullock BP, Heller RS, Habener JF. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 1996;137(7):2968-78.
6. Buse 2004 Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD, et al.Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27(11):2628-35.
7. Butler 2003 Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003;52(1):102-10.
8. Cohen 1960 Cohen J. A coefficient of agreement for nominal scales. Educational and Psychological Measurement 1960;20:37-46.
9. DeFronzo 2005 DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2. Diabetes Care 2005;28(5):1092-100.
10. Drucker 1987 Drucker DJ, Philippe J, Mojsov S, Chick WL, Habener JF. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proceedings of the National Academy of Sciences of the United States of America 1987;84(10):3434- 38.
11. Farilla 2003 Farilla L, Bulotta A, Hirshberg B, Li CS, Khoury N, Noushmehr H, et al.Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets.[see comment]. Endocrinology 2003;144(12):5149-58.
12. Fehmann 1992 Fehmann HC, Habener JF. Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells. Endocrinology 1992; 130(1):159-66.
13. Goke 1993 Goke R, Fehmann HC, Linn T, Schmidt H, Krause M, Eng J, Goke B. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. The Journal of biological chemistry 1993;268(26):19650-5.
14. Higgins 2002 Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002;21:1539-58.
15. Higgins 2003 Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analysis. BMJ 2003;327:557-60.
16. Higgins 2005 Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. In: The Cochrane Library 2005, Issue 3. Chichester, UK: John Wiley & Sons, Ltd.
17. Jadad 1996 Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al.Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled clinical trials 1996;17(1): 1-12.
18. Kendall 2005 Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, et al.Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28(5):1083-91.
19. Khan 2000 Khan KS, ter Riet G, Glanville J, Sowden A, Kleijnen J. Undertaking systematic reviews of research on effectiveness: CRD's guidance for those carrying out and commissioning reviews. CRD Report 4 (2nd edition) 2000.
20. Knudsen 2000 Knudsen LB, Nielsen PF, Huusfeldt PO, Johansen NL, Madsen K, Pedersen FZ, et al.Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. Journal of medicinal chemistry 4-5-2000;43(9):1664-9.
21. Kreymann 1987 Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 1987;2 (8571):1300-4.
22. Li 2003 Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. The Journal of biological chemistry 2003;278(1):471-8.
23. Madsbad 2004 Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care 2004;27(6):1335-42.
24. Maedler 2005 Maedler K, Carr RD, Bosco D, Zuellig RA, Berney T, Donath MY. Sulfonylurea induced beta-cell apoptosis in cultured human islets. The Journal of clinical endocrinology and metabolism 2005;90(1): 501-6.
25. Meier 2003 Meier JJ, Gallwitz B, Salmen S, Goetze O, Holst JJ, Schmidt W, et al.Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. The Journal of clinical endocrinology and metabolism 2003;88(6):2719-25.
26. Moher 1999 Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 1999;354(9193):1896-900.
27. Nauck 1993 Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993;36(8):741-4.
28. Nauck 2002 Nauck MA, Heimesaat MM, Behle K, Holst JJ, Nauck MS, Ritzel R, Hufner M, Schmiegel WH. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. The Journal of clinical endocrinology and metabolism 2002;87(3):1239-46.
29. Schulz 1995 Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408- 12.
30. Thorens 1992 Thorens B. Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proceedings of the National Academy of Sciences of the United States of America 1992; 89(18):8641-5.
31. Turner 1996 Turner RC, Holman RR. The UK Prospective Diabetes Study. UK Prospective Diabetes Study Group. Annals of medicine 1996;28(5): 439-44.
32. WHO 1980 WHO Expert Committee on Diabetes Mellitus. Second report. Technical Report Series 646. Geneva. WHO, 1980.
33. WHO 1985 WHO Expert Committee on Diabetes Mellitus. World Health Organization, 1985. Technical Report Series 727.
34. WHO 1998 Alberti KM, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its compliactions. Part I: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabetic Medicine 1998;15:539-53.
35. Xu 1999 Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999;48(12):2270-6.
36. Zander 2002 Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002;359(9309):824-30.